NCT06433505View on ClinicalTrials.gov

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

February 14, 2025

Study Completion Date

February 28, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986365

Specified dose on specified days

DRUG

[14C] BMS-986365

Specified dose on specified days.

DRUG

[14C] BMS-986409 + BMS-986410

Specified dose on specified days

DRUG

[14C] BMS-986410 + BMS-986409

Specified dose on specified days

Trial Locations (1)

53704

Local Institution - 0001, Madison

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY